TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) CEO Harlan F. Weisman Purchases 150,000 Shares

TFF Pharmaceuticals, Inc. (NASDAQ:TFFPGet Rating) CEO Harlan F. Weisman acquired 150,000 shares of the firm’s stock in a transaction dated Friday, March 10th. The shares were bought at an average cost of $0.88 per share, with a total value of $132,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 214,615 shares of the company’s stock, valued at $188,861.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

TFF Pharmaceuticals Stock Up 8.0 %

TFFP opened at $0.78 on Tuesday. The firm has a 50 day moving average price of $0.90 and a 200-day moving average price of $2.11. TFF Pharmaceuticals, Inc. has a twelve month low of $0.62 and a twelve month high of $7.70. The stock has a market capitalization of $27.15 million, a price-to-earnings ratio of -0.57 and a beta of 1.21.

Institutional Trading of TFF Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TFFP. Two Sigma Investments LP purchased a new stake in TFF Pharmaceuticals during the fourth quarter valued at approximately $60,000. Quantum Private Wealth LLC purchased a new stake in TFF Pharmaceuticals during the second quarter valued at approximately $62,000. Renaissance Technologies LLC purchased a new stake in TFF Pharmaceuticals during the fourth quarter valued at approximately $76,000. Virtu Financial LLC purchased a new stake in TFF Pharmaceuticals during the third quarter valued at approximately $84,000. Finally, Sigma Planning Corp increased its holdings in TFF Pharmaceuticals by 31.2% during the fourth quarter. Sigma Planning Corp now owns 100,891 shares of the company’s stock valued at $106,000 after buying an additional 24,000 shares during the last quarter. 16.46% of the stock is owned by hedge funds and other institutional investors.

TFF Pharmaceuticals Company Profile

(Get Rating)

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.

Recommended Stories

Insider Buying and Selling by Quarter for TFF Pharmaceuticals (NASDAQ:TFFP)

Receive News & Ratings for TFF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TFF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.